The prognostic significance of BMP-6 signaling in prostate cancer

Modern Pathology

Volumn 21, Issue 12, 2008, Pages 1436-1443

  Yuen, Hiu Fung ^a   Chan, Yuen Piu ^a   Cheung, Wai Lok ^a   Wong, Yong Chuan ^a   Wang, Xianghong ^a   Chan, Kwok Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

BMP 6; Metastasis; Noggin; Prostate cancer; Sclerostin

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; NOGGIN; SCLEROSTIN;

ADULT; AGED; ARTICLE; CANCER GROWTH; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION;

AGED; BONE MORPHOGENETIC PROTEIN 6; BONE MORPHOGENETIC PROTEINS; CARRIER PROTEINS; DISEASE PROGRESSION; GENETIC MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 56649114367     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.94     Document Type: Article

References (28)

1. Bentley H, Hamdy F, Hart K, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-1163.
2. van Tol-Geerdink J, Stalmeier P, van Lin E, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol 2006;24:4581-4586.
3. Loberg R, Gayed B, Olson K, et al. A paradigm for the treatment of prostate cancer bone metastases based on an understanding of tumor cell-microenvironment interactions. J Cell Biochem 2005;96:439-446.
4. Barnes J, Anthony C, Wall N, et al. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 1995;13:337-343.
5. Hamdy F, Autzen P, Robinson M, et al. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 1997;57:4427-4431.
6. Autzen P, Robson C, Bjartell A, et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer 1998;78:1219-1223.
7. Dai J, Keller J, Zhang J, et al. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005;65:8274-8285.
8. Darby S, Cross S, Brown N, et al. BMP-6 overexpression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. J Pathol 2008;214:394-404.
9. Yanagita M. BMP antagonists: their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev 2005;16:309-317.
10. Gazzerro E, Gangji V, Canalis E. Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 1998;102:2106-2114.
11. Sutherland M, Geoghegan J, Yu C, et al. Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts. Bone 2004;35:448-454.
12. Haudenschild D, Palmer S, Moseley T, et al. Bone morphogenetic protein (BMP)-6 signaling and BMP antagonist noggin in prostate cancer. Cancer Res 2004;64:8276-8284.
13. Ye L, Lewis-Russell J, Kynaston H, et al. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists. J Urol 2007;178:1086-1091.
14. Winkler D, Yu C, Geoghegan J, et al. Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279:36293-36298.
15. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994-999.
16. Feeley B, Gamradt S, Hsu W, et al. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 2005;20:2189-2199.
17. Feeley B, Krenek L, Liu N, et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006;38:154-166.
18. Schwaninger R, Rentsch C,Wetterwald A, et al. Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. Am J Pathol 2007;170:160-175.
19. Kusu N, Laurikkala J, Imanishi M, et al. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003;278:24113-24117.
20. Yuen H, Chua C, Chan Y, et al. Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 2006;19:931-941.
21. Yuen H, Chan Y, Chan K, et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2007;97:1409-1415.
22. Harnden P, Shelley M, Coles B, et al. Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 2007;8:411-419.
23. Raida M, Sarbia M, Clement J, et al. Expression, regulation and clinical significance of bone morphogenetic protein 6 in esophageal squamous-cell carcinoma. Int J Cancer 1999;83:38-44.
24. Sulzbacher I, Birner P, Trieb K, et al. The expression of bone morphogenetic proteins in osteosarcoma and its relevance as a prognostic parameter. J Clin Pathol 2002;55:381-385.
25. Clement J, Sänger J, Höffken K. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor. Int J Cancer 1999;80:250-256.
26. Alarmo E, Rauta J, Kauraniemi P, et al. Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes Cancer 2006;45:411-419.
27. Kleeff J, Maruyama H, Ishiwata T, et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 1999;116:1202-1216.
28. Rothhammer T, Poser I, Soncin F, et al. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res 2005;65:448-456.